FORM
... 9) If the P-Q Segment of an ECG was longer than normal, you would be observing a ___________heart block. a) First degree b) Second degree c) Third degree d) Sinus rhythm e) Ectopic foci 10) Which have the fastest rate of conduction (about 3 meters/second) in the heart? a) Atrial myocytes b) AV Node ...
... 9) If the P-Q Segment of an ECG was longer than normal, you would be observing a ___________heart block. a) First degree b) Second degree c) Third degree d) Sinus rhythm e) Ectopic foci 10) Which have the fastest rate of conduction (about 3 meters/second) in the heart? a) Atrial myocytes b) AV Node ...
The Pharmacology of Heart Failure
... Rule of thumb: 1-2.5 times their normal PO dose Peak diuresis is 30 minutes after administration Bolus and continuous IV infusions have similar efficacy Adding a thiazide diuretic (metolazone) can potentiate the effects of the loop diuretics ...
... Rule of thumb: 1-2.5 times their normal PO dose Peak diuresis is 30 minutes after administration Bolus and continuous IV infusions have similar efficacy Adding a thiazide diuretic (metolazone) can potentiate the effects of the loop diuretics ...
Starter Qs
... • Describe the action of the SAN on the cardiac muscle cells, including how this stimulates the AVN • Identify SAN and AVN locations in a diagram • State the role of an ECG • Interpret ECG graphs in order to calculate heart rate • State that the heart beat can be regulated by both nervous and ...
... • Describe the action of the SAN on the cardiac muscle cells, including how this stimulates the AVN • Identify SAN and AVN locations in a diagram • State the role of an ECG • Interpret ECG graphs in order to calculate heart rate • State that the heart beat can be regulated by both nervous and ...
910 Electrocardiography - European Heart Journal
... United States of America; 3 Johns Hopkins University, Baltimore, United States of America; 4 Wake Forest University Health Sciences, Winston-Salem, United States of America; 5 Washington University, Washington, United States of America; 6 Johns Hopkins University School of Medicine, Johns Hopkins Ho ...
... United States of America; 3 Johns Hopkins University, Baltimore, United States of America; 4 Wake Forest University Health Sciences, Winston-Salem, United States of America; 5 Washington University, Washington, United States of America; 6 Johns Hopkins University School of Medicine, Johns Hopkins Ho ...
differential diagnosis for dilated cardiomyopathy from ischemic heart
... T. Hiroahshi, K. Kurosu, K. Shimizu, T. Tomaru Dept of Clinical Physiology, Toho University Medical School, Sakura, Japan We evaluated usefulness of the presence of carotid arteriosclerosis for differential diagnosis of dilated cardiomyopathy (DCM) from ischemic heart disease (IHD) Methods: We evalu ...
... T. Hiroahshi, K. Kurosu, K. Shimizu, T. Tomaru Dept of Clinical Physiology, Toho University Medical School, Sakura, Japan We evaluated usefulness of the presence of carotid arteriosclerosis for differential diagnosis of dilated cardiomyopathy (DCM) from ischemic heart disease (IHD) Methods: We evalu ...
שקופית 1
... • Minimally invasive circulatory assist device, provides short term solution as a bridge to decision or as a bridge to bridge (LVAD). • 3 l/m circulatory support in severe left ventricular failure and during high-risk revascularisation procedures. ...
... • Minimally invasive circulatory assist device, provides short term solution as a bridge to decision or as a bridge to bridge (LVAD). • 3 l/m circulatory support in severe left ventricular failure and during high-risk revascularisation procedures. ...
Congestive Heart Failure (CHF)
... Congestive Heart Failure (CHF) About 5 million people in the United States have some form of heart failure, and nearly 550,000 new cases are diagnosed each year. The risk of developing heart failure increases with age, and it is estimated that one out of every 10 people over the age of 65 will be di ...
... Congestive Heart Failure (CHF) About 5 million people in the United States have some form of heart failure, and nearly 550,000 new cases are diagnosed each year. The risk of developing heart failure increases with age, and it is estimated that one out of every 10 people over the age of 65 will be di ...
Cardiovascular System 1 - University of Manitoba
... Heart chamber with thicker wall Provides information about electrical activity of heart (abbr) Nervous system controller of heart rate (abbr) Too rapid ventricular contraction Heart sound marking closure of aortic and pulmonary valves Pouch-like atrial appendage Drugs that breakup blood clots ...
... Heart chamber with thicker wall Provides information about electrical activity of heart (abbr) Nervous system controller of heart rate (abbr) Too rapid ventricular contraction Heart sound marking closure of aortic and pulmonary valves Pouch-like atrial appendage Drugs that breakup blood clots ...
Literature Reviews
... endocardial fibrosis. All these patients had intact circumferential strain, as the disease did not affect the mid-myocardial fiber layers. These patients had intact twist as the subepicardial counterclockwise rotation overcomes the subendocardial clockwise rotation. The limitations of the study as p ...
... endocardial fibrosis. All these patients had intact circumferential strain, as the disease did not affect the mid-myocardial fiber layers. These patients had intact twist as the subepicardial counterclockwise rotation overcomes the subendocardial clockwise rotation. The limitations of the study as p ...
Patients Slide 1 Slide 1 Slide 1 Slide 1Patients Slide 1 Slide 1 Slide
... Sheffield • Since 2012, and every month there has been a 6.2% increase in the number of tests. • Interestingly the rise was mainly at the expense of rising negative tests (<400) • Within the positive tests, the rise has been mainly in those with NTproBNP 400-2000 • Not all those with a positive test ...
... Sheffield • Since 2012, and every month there has been a 6.2% increase in the number of tests. • Interestingly the rise was mainly at the expense of rising negative tests (<400) • Within the positive tests, the rise has been mainly in those with NTproBNP 400-2000 • Not all those with a positive test ...
Lab Check 09th edition
... Because each QRS wave in the pattern indicates a ventricular contraction, the heart rate can be determined by counting the QRS waves that occur in a minute. (experimental results) ...
... Because each QRS wave in the pattern indicates a ventricular contraction, the heart rate can be determined by counting the QRS waves that occur in a minute. (experimental results) ...
CRT-D - Medtronic
... Medtronic CRT-D Systems Indications: Medtronic Cardiac Resynchronization Therapy Implantable Cardioverter-Defibrillators (CRT-Ds) are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias and for providing ...
... Medtronic CRT-D Systems Indications: Medtronic Cardiac Resynchronization Therapy Implantable Cardioverter-Defibrillators (CRT-Ds) are indicated for ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias and for providing ...
cardiology - CatsTCMNotes.com
... can be lethal (sudden cardiac death), symptomatic (syncope, near syncope, dizziness, fatigue, or palpitations), or asymptomatic reduce cardiac output, perfusion of the brain or myocardium is impaired ...
... can be lethal (sudden cardiac death), symptomatic (syncope, near syncope, dizziness, fatigue, or palpitations), or asymptomatic reduce cardiac output, perfusion of the brain or myocardium is impaired ...
Mechanical dyssynchrony provides the clue Erwan DONAL
... The power to predict CRT response differs between indices of mechanical dyssynchrony. SRSsept and IVMD better represent LV dyssynchrony amenable to CRT and better predict CRT response than the indices assessing time-to-peak deformation or motion. Circ Cardiovasc Imaging. 2012;5:491-499. ...
... The power to predict CRT response differs between indices of mechanical dyssynchrony. SRSsept and IVMD better represent LV dyssynchrony amenable to CRT and better predict CRT response than the indices assessing time-to-peak deformation or motion. Circ Cardiovasc Imaging. 2012;5:491-499. ...
Rationale for the Atrial Fibrillation and Congestive Heart Failure (AF
... irregularity of ventricular response, and loss of atrial contraction associated with AF may result in adverse hemodynamic consequences and influence prognosis in patients with CHF [4-15] . Restoration of sinus rhythm has been associated with improvement in cardiac output, exercise capacity, and maxi ...
... irregularity of ventricular response, and loss of atrial contraction associated with AF may result in adverse hemodynamic consequences and influence prognosis in patients with CHF [4-15] . Restoration of sinus rhythm has been associated with improvement in cardiac output, exercise capacity, and maxi ...
Chapter 37
... One or more of the mitral valve leaflets prolapses back into the left atrium during systole Usually congenital Usually benign, but can be problematic if it progresses to mitral regurgitation Most people asymptomatic, but manifestations may include CP, dyspnea and palpitations ...
... One or more of the mitral valve leaflets prolapses back into the left atrium during systole Usually congenital Usually benign, but can be problematic if it progresses to mitral regurgitation Most people asymptomatic, but manifestations may include CP, dyspnea and palpitations ...
ventricular fibrillation - pulseless ventricular tachycardia (a01)
... placement of an endotracheal tube will interrupt compressions for more than 10 seconds. TEST FOR GLUCOSE. DEXTROSE - If blood glucose < 75 mg/dL, 25 – 50 gms IV/IO. NALOXONE - 0.4 – 2 mg IV/IO/IN (if narcotic use is suspected). SODIUM BICARBONATE - 1 mEq/kg IV/IO for known or suspected hyperkalemia. ...
... placement of an endotracheal tube will interrupt compressions for more than 10 seconds. TEST FOR GLUCOSE. DEXTROSE - If blood glucose < 75 mg/dL, 25 – 50 gms IV/IO. NALOXONE - 0.4 – 2 mg IV/IO/IN (if narcotic use is suspected). SODIUM BICARBONATE - 1 mEq/kg IV/IO for known or suspected hyperkalemia. ...
Cardiac Electrophysiology
... A 68 year old female arrives at the emergency room in an ambulance. That evening she had been feeling “weak and dizzy” after ingesting a handful of her “heart pills” and later passed out. Her heart rate was irregular but near 33 beats per minute. Her patient records and talks with her family reveale ...
... A 68 year old female arrives at the emergency room in an ambulance. That evening she had been feeling “weak and dizzy” after ingesting a handful of her “heart pills” and later passed out. Her heart rate was irregular but near 33 beats per minute. Her patient records and talks with her family reveale ...
2010-cardiovascular
... E. nifedipine 6. The mechanism of anti-hypertensive effect of losartan is: A. decrement of renin activity B. inhibition of angiotensin converting enzyme C. blockade of the angiotensin Ⅱ receptors D. increment of bradykinin synthesis E. causing vasodilation directly 7. The antihypertensive mechanism ...
... E. nifedipine 6. The mechanism of anti-hypertensive effect of losartan is: A. decrement of renin activity B. inhibition of angiotensin converting enzyme C. blockade of the angiotensin Ⅱ receptors D. increment of bradykinin synthesis E. causing vasodilation directly 7. The antihypertensive mechanism ...
Chapter 20
... 1. rapid depolarization 2. the plateau 3. repolarization -Has both absolute and relative refractory periods B) source of Ca2+ ions -as an AP arrives, calcium concentration increases in two steps: 1. calcium ions enter from extracellular space 2. this extracellular calcium triggers more Ca2+ release ...
... 1. rapid depolarization 2. the plateau 3. repolarization -Has both absolute and relative refractory periods B) source of Ca2+ ions -as an AP arrives, calcium concentration increases in two steps: 1. calcium ions enter from extracellular space 2. this extracellular calcium triggers more Ca2+ release ...
NOW Graduate Programme 2010 – CARIM proposal
... Main contributions to congresses, memberships of scientific societies International activities ...
... Main contributions to congresses, memberships of scientific societies International activities ...
Pacers, ablation, cardioversion, telemetry, Intro to ACLS
... heart pumps out to body in 1 min. NORMAL: 5 to 8 L • CO= HR x SV (CO can be changed by altering heart rate, stroke vol. or both) • Stroke Volume = the amount of blood that the ...
... heart pumps out to body in 1 min. NORMAL: 5 to 8 L • CO= HR x SV (CO can be changed by altering heart rate, stroke vol. or both) • Stroke Volume = the amount of blood that the ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.